Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10430
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTestro, Adam G-
dc.contributor.authorWongseelashote, Sarah-
dc.contributor.authorAngus, Peter W-
dc.contributor.authorGow, Paul J-
dc.date.accessioned2015-05-15T23:52:36Z
dc.date.available2015-05-15T23:52:36Z
dc.date.issued2008-09-03-
dc.identifier.citationJournal of Gastroenterology and Hepatology 2008; 23(10): 1535-40en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10430en
dc.description.abstractStudies suggest that terlipressin is effective in the treatment of hepatorenal syndrome (HRS). However, factors predicting response to therapy and the long-term outcome of patients have not been defined.We reviewed all patients from our institution treated with terlipressin between July 1, 2001 and December 31, 2005 for HRS. Follow up continued until June 30, 2006. HRS was defined according to the International Ascites Club. The following data were retrieved: age, gender, etiology of liver disease, Child-Pugh score, HRS precipitant, therapy duration, creatinine at day 0 and end of treatment, adverse events, and patient outcome.Sixty-nine patients were included. Forty-nine episodes (71%) of HRS were type 1, and 20 episodes (29%) type 2. Forty-one (59.4%) patients responded to terlipressin. Two variables predicted renal function improvement: type 1 HRS and age. Twenty-one (30.4%) patients survived; 17 (81%) had type 1 HRS while four (19%) had type 2 HRS (P = 0.27). The only factor predicting transplant-free survival was type 1 HRS. No patients with type 2 HRS survived without transplantation (P = 0.02).The only factor predicting transplant-free survival following terlipressin therapy is the presence of type 1 HRS. Therefore, it is difficult to justify the use of this drug in patients with type 2 HRS who are not liver transplant candidates.en_US
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherCardiovascular Agents.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHepatorenal Syndrome.drug therapy.mortality.physiopathology.surgeryen
dc.subject.otherHumansen
dc.subject.otherKaplan-Meier Estimateen
dc.subject.otherKidney.drug effects.physiopathologyen
dc.subject.otherLiver Transplantationen
dc.subject.otherLypressin.analogs & derivatives.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPatient Selectionen
dc.subject.otherRetrospective Studiesen
dc.subject.otherRisk Assessmenten
dc.subject.otherSeverity of Illness Indexen
dc.subject.otherTime Factorsen
dc.subject.otherTreatment Outcomeen
dc.titleLong-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Gastroenterology and Hepatologyen_US
dc.identifier.affiliationVictorian Liver Transplant Uniten_US
dc.identifier.affiliationGastroenterology and Hepatologyen_US
dc.identifier.doi10.1111/j.1440-1746.2007.05176.xen_US
dc.description.pages1535-40en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17784863en
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherAngus, Peter W
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.